All Phenotypes Gt(ROSA)26Sor<tm11(Lmp1)Rsky> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺	involves: C57BL/6	MGI:5314101
cn2	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb⁺ Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5314091
cn3	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:5314096
cn4	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Klrk1^tm1Dhr/Klrk1^tm1Dhr Cd19^tm1(cre)Cgn/Cd19⁺	involves: 129P2/OlaHsd * C57BL/6	MGI:5314087
cn5	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺	involves: 129P2/OlaHsd * C57BL/6	MGI:5314104
cn6	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Cd19^{tm1(cre/ERT2)Rsky}/Cd19⁺	involves: 129P2/OlaHsd * C57BL/6J	MGI:5614487

Allelic Composition	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky} mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased B cell proliferation ( J:181546 )

• B cells treated with TAT-cre proliferate in culture unlike wild-type cells

abnormal B cell morphology ( J:181546 )

• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells

hematopoietic system

increased B cell proliferation ( J:181546 )

• B cells treated with TAT-cre proliferate in culture unlike wild-type cells

abnormal B cell morphology ( J:181546 )

• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells

cellular

increased B cell proliferation ( J:181546 )

• B cells treated with TAT-cre proliferate in culture unlike wild-type cells

Allelic Composition	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb⁺ Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺
Genetic Background	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19^tm1(cre)Cgn mutation (12 available); any Cd19 mutation (57 available)
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky} mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)
Tcrb^tm1Mom mutation (12 available); any Tcrb mutation (99 available)
Tcrd^tm1Mom mutation (13 available); any Tcrd mutation (15 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:181546 )

immune system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

hematopoietic system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

growth/size/body

enlarged spleen ( J:181546 )

Allelic Composition	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Tcrb^tm1Mom/Tcrb^tm1Mom Tcrd^tm1Mom/Tcrd^tm1Mom Cd19^tm1(cre)Cgn/Cd19⁺
Genetic Background	involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:181546 )

immune system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

liver/biliary system

enlarged liver ( J:181546 )

• occasionally

neoplasm

increased B cell derived lymphoma incidence ( J:181546 )

• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)

increased plasmacytoma incidence ( J:181546 )

• in 3 of 9 mice

hematopoietic system

enlarged spleen ( J:181546 )

increased B cell number ( J:181546 )

growth/size/body

enlarged liver ( J:181546 )

• occasionally

enlarged spleen ( J:181546 )

Allelic Composition	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Klrk1^tm1Dhr/Klrk1^tm1Dhr Cd19^tm1(cre)Cgn/Cd19⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19^tm1(cre)Cgn mutation (12 available); any Cd19 mutation (57 available)
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky} mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)
Klrk1^tm1Dhr mutation (3 available); any Klrk1 mutation (24 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:181546 )

N	• mice are protected from Lmp1-driven lymphomagenesis

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

immune system

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

abnormal B cell differentiation ( J:181546 )

• impaired in the bone marrow

increased pro-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased B cell number ( J:181546 )

• at 6 to 12 weeks in the spleen and bone marrow

• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen

decreased mature B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased pre-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

increased B cell number ( J:181546 )

• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice

increased CD4-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

increased CD8-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

abnormal immune system physiology ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit splenomegaly and become terminally ill unlike control mice

increased B cell proliferation ( J:181546 )

• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

abnormal CD4-positive, alpha-beta T cell physiology ( J:181546 )

• in an in vitro tumor killing assay, CD4+ T cells exhibit reduced tumor killing compared with control cells

• however, CD4+ T cells exhibit normal prevention of tumor outgrowth in vivo and elimination of nontransformed L,p1+ B cells upon transfer

abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )

• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

• in vivo, CD8+ T cells exhibit reduced prevention of tumor outgrowth compared with control cells

• however, CD8+ T cell exhibit normal tumor killing in vitro and elimination of nontransformed L,p1+ B cells upon transfer

increased interferon-gamma secretion ( J:181546 )

• minor in T cells co-cultured with tumor or B cells

increased tumor necrosis factor secretion ( J:181546 )

• minor in T cells co-cultured with tumor or B cells

hematopoietic system

increased B cell proliferation ( J:181546 )

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

abnormal B cell differentiation ( J:181546 )

• impaired in the bone marrow

increased pro-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased B cell number ( J:181546 )

• at 6 to 12 weeks in the spleen and bone marrow

• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen

decreased mature B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

decreased pre-B cell number ( J:181546 )

• at 6 to 12 weeks in the bone marrow

increased B cell number ( J:181546 )

• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice

increased CD4-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

increased CD8-positive, alpha-beta T cell number ( J:181546 )

• at P8, but not P3, in the spleen

• of activated T cells in the bone marrow at 6 to 12 weeks

abnormal CD4-positive, alpha-beta T cell physiology ( J:181546 )

• in an in vitro tumor killing assay, CD4+ T cells exhibit reduced tumor killing compared with control cells

• however, CD4+ T cells exhibit normal prevention of tumor outgrowth in vivo and elimination of nontransformed L,p1+ B cells upon transfer

abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )

• in vivo, CD8+ T cells exhibit reduced prevention of tumor outgrowth compared with control cells

• however, CD8+ T cell exhibit normal tumor killing in vitro and elimination of nontransformed L,p1+ B cells upon transfer

growth/size/body

enlarged spleen ( J:181546 )

• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

cellular

increased B cell proliferation ( J:181546 )

• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

Allelic Composition	Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/Gt(ROSA)26Sor⁺ Cd19^{tm1(cre/ERT2)Rsky}/Cd19⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19^{tm1(cre/ERT2)Rsky} mutation (1 available); any Cd19 mutation (57 available)
Gt(ROSA)26Sor^{tm11(Lmp1)Rsky} mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

enlarged spleen ( J:217520 )

• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

increased B cell number ( J:217520 )

• CD19+ B cells in tamoxifen-treated mice

• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion

increased CD4-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased CD8-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased activated T cell number ( J:217520 )

• in tamoxifen-treated mice

• however, T cell numbers decrease 8 days after tamoxifen application

abnormal T cell physiology ( J:217520 )

• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro

hematopoietic system

enlarged spleen ( J:217520 )

• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

increased B cell number ( J:217520 )

• CD19+ B cells in tamoxifen-treated mice

• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion

increased CD4-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased CD8-positive, alpha-beta T cell number ( J:217520 )

• massive expansion in tamoxifen-treated mice

increased activated T cell number ( J:217520 )

• in tamoxifen-treated mice

• however, T cell numbers decrease 8 days after tamoxifen application

abnormal T cell physiology ( J:217520 )

• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro

growth/size/body

enlarged spleen ( J:217520 )

• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 09/30/2025 MGI 6.24